318 related articles for article (PubMed ID: 30730576)
81. A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy.
Alshabi A; Shaik IH; Zhao Y; Pillai VC; Caritis S; Venkataramanan R
Eur J Clin Pharmacol; 2023 Jun; 79(6):815-827. PubMed ID: 37060457
[TBL] [Abstract][Full Text] [Related]
82. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment.
Bu HZ; Knuth K; Magis L; Teitelbaum P
Rapid Commun Mass Spectrom; 2000; 14(20):1943-8. PubMed ID: 11013424
[TBL] [Abstract][Full Text] [Related]
83. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery.
Smith D; Sadagopan N; Zientek M; Reddy A; Cohen L
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):455-63. PubMed ID: 17270503
[TBL] [Abstract][Full Text] [Related]
84. An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes.
Wang JJ; Guo JJ; Zhan J; Bu HZ; Lin JH
J Pharm Anal; 2014 Aug; 4(4):270-278. PubMed ID: 29403890
[TBL] [Abstract][Full Text] [Related]
85. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity.
De Bock L; Boussery K; Colin P; De Smet J; T'jollyn H; Van Bocxlaer J
Talanta; 2012 Jan; 89():209-16. PubMed ID: 22284482
[TBL] [Abstract][Full Text] [Related]
86. High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.
Oh KS; Park SJ; Shinde DD; Shin JG; Kim DH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():56-64. PubMed ID: 22483397
[TBL] [Abstract][Full Text] [Related]
87. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
88. [Effect of oligosaccharide esters and polygalaxanthone Ill from Polygala tenuifolia willd towards cytochrome P450].
Li ZL; Dong XZ; Wang DX; Dong RH; Guo TT; Sun Y; Liu P
Zhongguo Zhong Yao Za Zhi; 2014 Nov; 39(22):4459-63. PubMed ID: 25850285
[TBL] [Abstract][Full Text] [Related]
89. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
90. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
91. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
92. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
93. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
94. Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites.
Tanaka S; Uchida S; Inui N; Takeuchi K; Watanabe H; Namiki N
Biol Pharm Bull; 2014; 37(1):18-25. PubMed ID: 24389476
[TBL] [Abstract][Full Text] [Related]
95. Interaction between Changan Granule and its main components in the plasma and CYP450 enzymes.
Liu X; Wang Q; Chen M; Tao J; Wang J; Liu S; Hou J; Li D; Wang R
J Ethnopharmacol; 2023 May; 308():116303. PubMed ID: 36841379
[TBL] [Abstract][Full Text] [Related]
96. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.
Zientek M; Youdim K
Methods Mol Biol; 2013; 987():11-23. PubMed ID: 23475664
[TBL] [Abstract][Full Text] [Related]
97. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
[TBL] [Abstract][Full Text] [Related]
98. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
99. Evaluation of acacetin inhibition potential against cytochrome P450 in vitro and in vivo.
Zhou Y; Tu Y; Zhou Q; Hua A; Geng P; Chen F; Han A; Liu J; Dai D; Wang S; Wang J; Wen C
Chem Biol Interact; 2020 Sep; 329():109147. PubMed ID: 32738202
[TBL] [Abstract][Full Text] [Related]
100. The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation.
Park SH; Lee J; Shon JC; Phuc NM; Jee JG; Liu KH
Phytomedicine; 2018 Mar; 42():199-206. PubMed ID: 29655687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
